Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2022-03-25 Board/Management Inform…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment and resignation of outside directors (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This falls under the category of board and management changes.
2022-03-25 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for Samil Pharmaceutical Co., Ltd. for the fiscal year 2021. It includes the independent auditor's report, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows), and detailed notes. This is a formal, full-year financial audit document, which falls under the 'Audit Report / Information' category. FY 2021
2022-03-16 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Samil Pharmaceutical regarding the adjustment of the exercise price of its bond with warrants (BW). It details the change in the exercise price from 8,805 KRW to 8,390 KRW due to a decline in the market price of the underlying stock. This type of disclosure is a standard regulatory requirement for companies with outstanding convertible or warrant-bearing debt to inform the market of changes in capital structure and potential dilution. Since it is a specific regulatory announcement regarding capital structure adjustments rather than a general report or a simple publication notice, it falls under the 'Capital/Financing Update' category.
2022-03-15 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Samil Pharmaceutical announcing the submission of its audit report (감사보고서 제출). It provides a summary of the audit opinion (unqualified/적정) and key financial highlights (assets, liabilities, revenue, profit/loss) for the fiscal year ending 2021-12-31. According to the 'Menu vs Meal' rule, this is an announcement of the audit report submission rather than the full audit report itself, making it a Report Publication Announcement (RPA). FY 2021
2022-03-14 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a previous disclosure of 'Changes in Sales or Profit/Loss Structure of 30% or more'. This type of filing is a standard regulatory disclosure required by the exchange when financial figures are updated due to audit finalization. It does not constitute a full Annual Report (10-K) or an Earnings Release (ER) itself, but rather a formal regulatory update. Therefore, it falls under the 'Regulatory Filings' category. FY 2021
2022-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Samil Pharmaceutical. It contains the meeting agenda, details on voting procedures (including electronic voting), and management reference materials (경영참고사항) such as financial statements and board activity reports. This type of document is standard for proxy solicitation and shareholder meeting materials, which falls under the 'Proxy Solicitation & Information Statement' category.
2022-03-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.